Charles River Laboratories International, Inc. (CRL) stock analysis
Healthcare · Diagnostics & Research
From the 10-K filed 2026-02-18
Business type: Franchise
How it makes money
Discovery and Safety Assessment generates 59.8% of revenue, charging biopharma clients for the regulated toxicology studies required for FDA drug approval.
The segment functions as a one-stop partner for the 10 to 15 year drug development cycle, utilizing a global 120-site infrastructure to handle outsourced safety testing.
In the Manufacturing segment, profits are driven by the Endosafe platform, which uses horseshoe crab extract to perform globally-mandated quality control testing on injectable drugs. The business model relies on the high volume of studies and the utilization rate of specialized vivarium space like CRADL.
What protects it: the moat
It maintains a moat through 140 proprietary rodent strains and a global network that provides essential diagnostics for regulated client research programs.
The company acts as the reference laboratory of choice for health assessment of research models, creating high switching costs for biopharma clients embedded in its diagnostic ecosystem.
Its competitive position is fortified by the vertical integration of its non-human primate supply chain and a portfolio of over 140 purpose-bred rodent stocks that are foundational to the non-clinical drug research process.
What could damage it
Federal investigations into Cambodian primate shipments caused a $27 million inventory write-down and can disrupt the $1.9 billion study backlog.
Because safety assessment depends on a limited supply of large animal models, legal challenges to imports directly impair the ability to execute booked studies. A grand jury subpoena regarding Cambodian shipments forced the company to write down the value of specific inventory to zero, demonstrating how supply chain volatility can permanently lose revenue attached to its safety assessment facilities.
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.